List view / Grid view

Prof. Klaus Dugi

Prof. Klaus Dugi serves as Corporate Senior Vice President of Medicine and Chief Medical Officer at Boehringer Ingelheim GmbH.

news

FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)

A new perspective from the U.S. FDA...

26 March 2013 | By Boehringer Ingelheim

A new perspective from the U.S. FDA...

news

Boehringer Ingelheim and Lilly initiate MARLINA™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria

Boehringer Ingelheim and Eli Lilly and Company announced today the…

19 March 2013 | By Boehringer Ingelheim

Boehringer Ingelheim and Eli Lilly and Company announced today the initiation of a Phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albuminuria, and urinary albumin-to-creatinine (UACR) ratio 30-3000 mg/g creatinine, in addition to current standard therapy for diabetic nephropathy.…

news

American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education with focus on China in 2013

International peer-to-peer sharing...

11 March 2013 | By Boehringer Ingelheim

International peer-to-peer sharing...

news

Boehringer Ingelheim announces interim results from a Phase III trial in HIV patients co-infected with chronic hepatitis C

Interim study results from STARTversoTM 4...

4 March 2013 | By Boehringer Ingelheim

Interim study results from STARTversoTM 4...

news

Phase III results: tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status

New Phase III data presented...

23 February 2013 | By Boehringer Ingelheim

New Phase III data presented...

news

FDA Advisory Committee recommends approval of olodaterol* for maintenance treatment of COPD

Olodaterol may provide a new treatment option in patients with…

29 January 2013 | By Boehringer Ingelheim

Olodaterol may provide a new treatment option in patients with COPD...

news

Boehringer Ingelheim and the EFSD call for grant applications in diabetes research

Submissions opened for diabetes research grant applications from across Europe...

17 January 2013 | By Boehringer Ingelheim

Submissions opened for diabetes research grant applications from across Europe...

news

Boehringer Ingelheim enrols first patients in pivotal Phase III interferon-free hepatitis C trial programme

"Diabetes affects more than 371m people..."

17 January 2013 | By Boehringer Ingelheim

"Diabetes affects more than 371m people..."

news

U.S. FDA grants priority review to Boehringer Ingelheim’s Afatinib* NDA for EGFR mutation-positive advanced NSCLC

The acceptance of the NDA filing reinforces our ongoing commitment…

16 January 2013 | By Boehringer Ingelheim

The acceptance of the NDA filing reinforces our ongoing commitment to oncology..."

news

Positive top-line pivotal Phase III data results for empagliflozin

Top-line results for four completed Phase III clinical trials...

7 January 2013 | By Boehringer Ingelheim

Top-line results for four completed Phase III clinical trials...

news

Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin

Results from a new post-hoc analysis...

10 December 2012 | By Boehringer Ingelheim

Results from a new post-hoc analysis...

news

Boehringer Ingelheim to initiate Phase III study in leukaemia with its compound volasertib* based on positive Phase II results

New positive Phase II results...

10 December 2012 | By Boehringer Ingelheim

New positive Phase II results...

news

Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease

Pivotal Phase III interferon-free study being initiated following positive Phase…

10 November 2012 | By Boehringer Ingelheim

Pivotal Phase III interferon-free study being initiated following positive Phase IIb results...

news

RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa®

Pivotal data from the RELY-ABLE® study have provided additional data...

8 November 2012 | By Boehringer Ingelheim

Pivotal data from the RELY-ABLE® study have provided additional data...

news

Recruitment complete for Trajenta® (linagliptin) cardiovascular outcome study in patients with Type 2 Diabetes

Boehringer Ingelheim and Eli Lilly and Company are pleased to…

8 November 2012 | By Boehringer Ingelheim

Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the recruitment of patients for CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes)1 has been completed. Linagliptin is currently the only DPP-4 inhibitor that is being compared to an active comparator in…

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Prof. Klaus Dugi